Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02409459 · ClinicalTrials.gov registry record · Phase 2
Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
A Phase 2 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT02409459 is a Phase 2 study that has completed, run by American Regent. The registered enrollment target is 81 participants.
The verdict
NCT02409459, a Phase 2 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days.
Interventions
- DRUG Placebo
- DRUG Injectafer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02409459
The ClinicalTrials.gov registry entry for NCT02409459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02409459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02409459 about?
NCT02409459 is a clinical study titled "Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia". This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety ...
What is the current status of trial NCT02409459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2015-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02409459?
The interventions under investigation include: Placebo (DRUG), Injectafer (DRUG).
Who is sponsoring clinical trial NCT02409459?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.